MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain
Portfolio Pulse from
MIRA Pharmaceuticals has successfully formulated Ketamir-2 into a topical treatment for localized neuropathic and inflammatory pain, expanding its pain management portfolio.
March 13, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MIRA Pharmaceuticals has developed a topical version of Ketamir-2 for localized neuropathic and inflammatory pain, broadening its product offerings in pain management.
The development of a topical formulation of Ketamir-2 represents a significant expansion of MIRA's product line, potentially increasing its market share in pain management. This innovation could attract investor interest and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100